It will be important to assess the impact of inhibitors of the PI3K-AKT-mTOR pathway in the near future to determine to what extent this pathway could be more efficient than the EGFR pathway for oesophageal cancer growth and progression. The gene discussed is AKT1; the disease is carcinoma of esophagus.